ClinicalTrials.gg
RecruitingNCT07672535Updated Nov 20, 2026

Inspiratory Muscle Training in Individuals With Multiple Sclerosis

An interventional study of High intensity interval IMT and Low intensity IMT in Multiple Sclerosis and Inspiratory Muscle Training, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 20, 2026Now RecruitingFirst site in Turkey (Türkiye)+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa — 5 open to participants now, 6 under way, none of them phase 3. Multiple Sclerosis · Istanbul University - Cerrahpasa.

Planned enrollment
4th of 10
48 · median 38
Started
2026
with 2 others
No phase
10 of 16
4 open now
Registered
15th of 16
by date

Among the 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 15th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system, characterized by inflammation, demyelination, and axonal degeneration, and primarily affects young adults. Muscle weakness, sensory disturbances, spasticity, pain, visual impairment, ataxia, fatigue, cognitive dysfunction, and respiratory complications are among the most commonly reported symptoms in individuals with MS. Although inspiratory muscle training has been shown to have beneficial effects in individuals with MS, the effects of different inspiratory muscle training intensities on respiratory muscle strength and pulmonary function have not been sufficiently investigated.

The primary aim of this study is to investigate the effectiveness and clinical feasibility of high-intensity interval inspiratory muscle training in individuals with MS. The secondary aim is to compare the effects of high-intensity interval inspiratory muscle training, low-intensity inspiratory muscle training, and conventional rehabilitation on respiratory muscle strength, pulmonary function, cough effectiveness, exercise capacity, lower extremity functional muscle strength, balance, fatigue, dysphagia severity, sleep quality, and quality of life in individuals with MS.

Participants will be randomly assigned to one of three groups: a high-intensity interval inspiratory muscle training group, a low-intensity inspiratory muscle training group, or a conventional rehabilitation group. All three groups will receive conventional rehabilitation, while the inspiratory muscle training groups will additionally receive their respective inspiratory muscle training programs. This study aims to be the first randomized controlled trial to evaluate the effects of high-intensity interval inspiratory muscle training in individuals with MS.

Read the detailed description

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system. Although the pathogenesis of the disease is not fully understood, genetic and environmental factors are thought to contribute to its development. Demyelinating plaques, the primary pathological hallmark of MS, are most commonly found in the optic nerves, brainstem, spinal cord, and periventricular white matter. The clinical manifestations of the disease vary depending on the regions of the central nervous system affected and the extent of inflammation and axonal demyelination. Respiratory function and respiratory muscle strength have been shown to be lower in individuals with MS compared with healthy individuals. The risk of death due to respiratory complications is approximately 12 times higher in the MS population than in the general population, and 47% of MS-related deaths are attributed to respiratory complications. These findings highlight the critical importance of early interventions targeting respiratory function.

Although inspiratory muscle training (IMT) has been shown to improve respiratory function, its effects on functional outcomes in individuals with MS have not been sufficiently investigated. However, these functional outcomes are important for improving quality of life and optimizing rehabilitation in individuals with MS. Furthermore, because studies investigating IMT in individuals with MS are limited, the optimal training protocol in terms of training frequency, intensity, and duration has not yet been clearly established. Recent studies have demonstrated that high-intensity interval IMT is effective in improving respiratory function, respiratory muscle strength, and functional capacity in individuals with chronic obstructive pulmonary disease, bronchiectasis, and heart failure, and that it is well tolerated by patients. To the best of our knowledge, no study has investigated the effects of this approach in individuals with MS.

This study is designed as a randomized controlled trial. A total of 48 individuals diagnosed with MS will be randomly assigned to one of three groups: high-intensity interval IMT, low-intensity IMT, or conventional rehabilitation. The intervention period will last 8 weeks. All three groups will receive conventional rehabilitation consisting of aerobic and resistance exercises. In addition, the IMT groups will receive either high-intensity interval IMT or low-intensity IMT. The primary outcome measures of the study are respiratory muscle strength, pulmonary function, and cough strength. Secondary outcome measures include exercise capacity, lower extremity functional muscle strength, balance, fatigue, dysphagia severity, sleep quality, and quality of life.

03

Conditions studied

  • Multiple Sclerosis
  • Inspiratory Muscle Training

Browse trials for

Keywords

  • multiple sclerosis
  • inspiratory muscle training
  • respiratory muscle training
  • respiratory muscle strength
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis (MS) according to the 2024 McDonald criteria
  • Expanded Disability Status Scale (EDSS) score ≥2 and \<6
  • Age between 18 and 65 years
  • (MMSE) score >24
  • Willingness to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Experiencing an MS relapse within the past three months
  • Presence of chronic cardiac or pulmonary diseases that may affect respiratory muscle strength and function, such as , asthma, interstitial lung disease, or heart failure
  • Presence of pulmonary infection
  • Presence of orthopedic problems
  • Presence of psychiatric disorders
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    High intensity interval IMT group

    High-intensity interval IMT and conventional rehabilitation

    Behavioral: High intensity interval IMT

  • Experimental
    Low intensity IMT group

    Low intensity IMT and conventional rehabilitation

    Behavioral: Low intensity IMT

  • Active comparator
    Conventional rehabilitation

    Conventional rehabilitation

    Behavioral: Conventional rehabilitation

Interventions

  • BehavioralHigh intensity interval IMT

    Participants with multiple sclerosis (MS) in this group will perform high intensity interval inspiratory muscle training (IMT) for 8 weeks, three times per week (one supervised by a physiotherapist and two home-based sessions). The protocol consists of 7 cycles of 2 minutes of exercise followed by 1 minute of rest, with each session lasting 21 minutes. Training intensity will start at 30% of maximal inspiratory pressure (MIP) and progressively increase to 70% by the third week. From week 4 onward, intensity will be maintained at 70% of MIP and adjusted according to tolerance, based on a Borg scale rating of 3-5. In addition, participants in this group will receive a conventional rehabilitation program for 8 weeks, consisting of three sessions per week: one supervised session conducted by a physiotherapist and two supervised home-based sessions.

  • BehavioralLow intensity IMT

    Participants with multiple sclerosis (MS) in this group will perform low intensity inspiratory muscle training (IMT) for 8 weeks, consisting of five sessions per week: one supervised by a physiotherapist and four home-based supervised sessions. The training will be performed as two daily sessions of 15 minutes each, totaling 30 minutes per day. Low intensity IMT will be conducted at 30% of maximal inspiratory pressure (MIP). Training intensity will be reassessed and adjusted to 30% of MIP every two weeks during supervised sessions, based on repeated MIP measurements. During training, participants will be instructed to maintain a seated position with the upper chest and shoulders in a relaxed posture. In addition, participants in this group will receive a conventional rehabilitation program for 8 weeks, consisting of three sessions per week: one supervised session conducted by a physiotherapist and two supervised home-based sessions.

  • BehavioralConventional rehabilitation

    Participants in this group will undergo a conventional rehabilitation program for 8 weeks, consisting of three sessions per week: one supervised by a physiotherapist and two home-based supervised sessions. Each session will last approximately 40 minutes. The program will include warm-up exercises, aerobic exercises, strengthening exercises, balance exercises, and cool-down exercises.

06

What researchers measure

Primary outcomes

  1. Maximal inspiratory pressure (MIP)

    In our study, respiratory muscle strength will be assessed using an electronic mouth pressure measurement device (MicroRPM Respiratory Pressure Meter). For maximal inspiratory pressure (MIP) measurement, participants will be asked to wear a nose clip and perform a maximal inspiratory effort lasting at least 1.5 seconds through a mouthpiece after maximal expiration. Measurements will be performed in a seated position with rest intervals between attempts. The highest value obtained from three consecutive trials will be recorded in cmH₂O. The best value will also be expressed as a percentage of predicted normal values according to age and sex.

    Time frame: From baseline to the end of the intervention at 8 weeks

  2. Maximal expiratory pressure (MEP)

    In our study, respiratory muscle strength will be assessed using an electronic mouth pressure measurement device (MicroRPM Respiratory Pressure Meter). For maximal expiratory pressure (MEP) measurement, participants will be asked to wear a nose clip and perform a maximal expiratory effort lasting at least 1.5 seconds through a mouthpiece after maximal inspiration. Measurements will be performed in a seated position with rest intervals between attempts. The highest value obtained from three consecutive trials will be recorded in cmH₂O. The best value will also be expressed as a percentage of predicted normal values according to age and sex.

    Time frame: From baseline to the end of the intervention at 8 weeks

  3. Forced Vital Capacity (FVC)

    The pulmonary function test will be performed using the COSMED Pony FX device in accordance with the American Thoracic Society and European Respiratory Society guidelines.

    Time frame: From baseline to the end of the intervention at 8 weeks

  4. Forced Expiratory Volume (FEV1)

    The pulmonary function test will be performed using the COSMED Pony FX device in accordance with the American Thoracic Society and European Respiratory Society guidelines.

    Time frame: From baseline to the end of the intervention at 8 weeks

  5. Tiffeneau Index (FEV1/FVC)

    The pulmonary function test will be performed using the COSMED Pony FX device in accordance with the American Thoracic Society and European Respiratory Society guidelines.

    Time frame: From baseline to the end of the intervention at 8 weeks

  6. Peak Expiratory Flow (PEF)

    The pulmonary function test will be performed using the COSMED Pony FX device in accordance with the American Thoracic Society and European Respiratory Society guidelines.

    Time frame: From baseline to the end of the intervention at 8 weeks

  7. Cough strength

    For assessment of cough strength, peak cough flow (PCF) will be measured using a peak flow meter (ExpiRite® Peak Flow Meter, China).

    Time frame: From baseline to the end of the intervention at 8 weeks

Secondary outcomes

  1. Exercise capacity

    Functional capacity is assessed using the 6-Minute Walk Test according to the criteria of the American Thoracic Society. Participants are instructed to walk as fast as possible, but without running, at their own pace along a 30-meter flat corridor for 6 minutes. The distance covered is recorded in meters.

    Time frame: From baseline to the end of the intervention at 8 weeks

  2. Lower Extremity Functional Capacity

    Lower extremity functional capacity will be assessed using the Five Times Sit-to-Stand Test. Participants will be seated in a chair without armrests, with their arms crossed over the chest, and will be instructed to stand up and sit down five times as quickly as possible. The time required to complete the test will be recorded.

    Time frame: From baseline to the end of the intervention at 8 weeks

  3. Balance

    Balance will be assessed using the Mini-BESTest. The Mini-BESTest is a 14-item short version of the Balance Evaluation Systems Test (BESTest) designed to assess static and dynamic balance impairments and underlying postural control mechanisms. It includes four domains: anticipatory postural control, reactive postural control, sensory orientation, and dynamic gait. Each item is scored from 0 to 2, with a total score ranging from 0 to 28, where higher scores indicate better balance performance.

    Time frame: From baseline to the end of the intervention at 8 weeks

  4. Balance

    Balance will be assessed using the Activities-specific Balance Confidence (ABC) Scale. The ABC Scale will be used to assess balance confidence during daily activities. Participants will rate their confidence in performing 16 different activities on a scale from 0% (no confidence) to 100% (complete confidence). The total score is calculated by averaging item scores, with higher scores indicating lower fear of falling.

    Time frame: From baseline to the end of the intervention at 8 weeks

  5. Fatigue level

    Fatigue will be assessed using the Fatigue Severity Scale (FSS). The FSS consists of 9 items rated on a 7-point Likert scale, where 1 indicates strong disagreement and 7 indicates strong agreement. Participants will rate the extent to which they agree with each statement. The total score is calculated by averaging the scores of all items. Higher scores indicate greater fatigue severity. A mean score of ≥4 is considered to indicate severe fatigue.

    Time frame: From baseline to the end of the intervention at 8 weeks

  6. Dysphagia severity

    Dysphagia severity will be assessed using the Eating Assessment Tool (EAT-10). The EAT-10 consists of 10 items rated on a 5-point scale ranging from 0 (no problem) to 4 (severe problem). The total score ranges from 0 to 40, with higher scores indicating greater swallowing impairment and increased risk of dysphagia.

    Time frame: From baseline to the end of the intervention at 8 weeks

  7. Sleep quality

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI evaluates sleep quality over the past month and consists of 24 items. Nineteen items are self-rated by the participant, while 5 items are completed by a bed partner or roommate. Each item is scored on a scale from 0 to 3, and the total score ranges from 0 to 21. A total score of ≤5 indicates good sleep quality, while a score of \>5 indicates poor sleep quality.

    Time frame: From baseline to the end of the intervention at 8 weeks

  8. The Multiple Sclerosis Quality of Life-54 (MSQOL-54)

    Quality of life will be assessed using the Multiple Sclerosis Quality of Life (MSQOL-54) scale. The MSQoL consists of two main domains: Composite Physical Health (CPH) and Composite Mental Health (CMH). The CPH domain includes eight subdomains (physical health, role limitations due to physical problems, pain, fatigue, social function, health perception, health distress, and sexual function), while the CMH domain includes five subdomains (emotional health, role limitations due to emotional problems, health distress, cognitive function, and overall quality of life. Both domains are scored on a 0-100 scale, with higher scores indicating better quality of life.

    Time frame: From baseline to the end of the intervention at 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2026
First posted
Jun 29, 2026
StartActual
Aug 20, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Jan 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Istanbul University-Cerrahpasa · Istanbul, Turkey (Türkiye)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Istanbul University-Cerrahpasa · Istanbul, Turkey (Türkiye)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07672535
Responsible party
Zelal Apaydın (Principal Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Jun 29, 2026
Start date
Aug 20, 2026
Primary completion
Aug 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion